15030-72-5

Basic information

• Product Name: Z-AIB-OH
• Synonyms: Z-AIB-OH;Z-ALPHA-ME-ALA-OH;Z-ALPHA-METHYLALANINE;Z-ALPHA-AMINOISOBUTYRIC ACID;Z-2-METHYLALANINE;Z-2-AMINOISOBUTYRIC ACID;N-ALPHA-CARBOBENZOXY-ALPHA-AMINOISOBUTYRIC ACID;N-CARBOBENZYLOXY-2-METHYLALANINE
• CAS NO: 15030-72-5
• Molecular Formula: C₁₂H₁₅NO₄
• Molecular Weight: 237.25
• EINECS: 1533716-785-6
• Mol File: 15030-72-5.mol

Chemical Properties

• Melting Point: 65-69 °C(lit.)
• Boiling Point: 379.78°C (rough estimate)
• Flash Point: 209.6 °C
• Appearance: White/Powder
• Density: 1.215
• Vapor Pressure: 6.56E-08mmHg at 25°C
• Refractive Index: 1.5200 (estimate)
• Storage Temp.: -20°C
• Solubility: soluble in Methanol
• PKA: 4.09±0.10(Predicted)
• BRN: 2218009
• CAS DataBase Reference: Z-AIB-OH(CAS DataBase Reference)
• NIST Chemistry Reference: Z-AIB-OH(15030-72-5)
• EPA Substance Registry System: Z-AIB-OH(15030-72-5)

Safety Data

• Hazard Codes: Xn
• Statements: 22-36/37/38
• Safety Statements: 24/25-26
• WGK Germany: 3
• Hazardous Substances Data: 15030-72-5(Hazardous Substances Data)

Usage

Chemical Properties

white powder

InChI:InChI=1/C12H15NO4/c1-12(2,10(14)15)13-11(16)17-8-9-6-4-3-5-7-9/h3-7H,8H2,1-2H3,(H,13,16)(H,14,15)/p-1

Upstream product

• 62-57-7 2-Aminoisobutyric acid 
• 1113-49-1 2-methylalanine ethyl ester 
• 501-53-1 benzyl chloroformate 
• 5938-34-1 2-amino-2-methyl-propanoic acid hydrochloride 
• 13139-17-8 N-(Benzyloxycarbonyloxy)succinimide 

Downstream Products

• 907564-67-4 Z-Aib-Phe-OEt 
• 79775-03-4 2-<2-(Benzyloxycarboxamido)-2-methylpropionamido>-2-methylpropionsaeure 
• 81484-33-5 N<α-(benzyloxycarbonylamino)isobutyryl>-L-isoleucine methyl ester 
• 83537-94-4 Benzyloxycarbonyl-α-aminoisobutyryl-α-aminoisobutyric acid tert butyl ester 
• 152972-10-6 Z-AIB-(L)-Phe-O-(t-Bu) 
• 112379-93-8 2-Benzyloxycarbonylamino-2-methyl-propionic acid 1-benzylcarbamoyl-1-methyl-ethyl ester 
• 145730-72-9 Z-Aib-β-Ala-OBu^t 
• 84758-69-0 Z-Aib-L-Ala-OtBu 
• 84758-67-8 methyl N-(2-(((benzyloxy)carbonyl)amino)-2-methylpropanoyl)glycinate 
• 3350-42-3 methyl N-(2-(((benzyloxy)carbonyl)amino)-2-methylpropanoyl)-L-alaninate 
• 132682-03-2 Z-Aib-Gly-OEt 
• 15030-91-8 N<α-(benzyloxycarbonylamino)isobutyryl>-L-proline methyl ester 
• 6671-25-6 2-(2-benzyloxycarbonylamino-2-methyl-propionylamino)-2-methylpropionic acid methyl ester 
• 141075-62-9 [1-((1S,2R)-2-Hydroxy-1-methylcarbamoyl-propylcarbamoyl)-1-methyl-ethyl]-carbamic acid benzyl ester 

Relevant articles and documents

Linear Oligopeptides. Part 147. Chemical and Crystallographic Study of the Reaction between Benzyloxycarbonyl Chloride and α-Aminoisobutyric Acid

From the reaction mixture of benzyloxycarbonyl chloride and α-aminoisobutyric acid three crystalline compounds were isolated and characterized by chromatographic and spectroscopic techniques and X-ray diffraction.Two of them are polymorphic forms of the N

CHEMICAL COMPOUNDS

A compound of formula (I), wherein Ar1, R21, R23, R24, R25, R26, R27, A, X, Y and W are as defined herein. The compounds of the present invention are inhibitors of hematopoietic prostaglandin D synthase (H-PGDS) and can be useful in the treatment of Duchenne muscular dystrophy. Accordingly, the invention is further directed to pharmaceutical compositions comprising a compound of the invention. The invention is still further directed to methods of inhibiting H-PGDS activity and treatment of disorders associated therewith using a compound of the invention or a pharmaceutical composition comprising a compound of the invention.

NOVEL COMPOUNDS FOR THE TREATMENT OF HEPATITIS C

The disclosure provides compounds of formula I, including their salts, as well as compositions and methods of using the compounds. The compounds have activity against hepatitis C virus (HCV) and may be useful in treating those infected with HCV.

PYRAZOLE DERIVATIVES AS SGC STIMULATORS

There are described imidazole and pyrazole derivatives which are useful as stimulators of sGC, particularly NO-independent, heme-dependent stimulators. These compounds are also useful for treating, preventing or managing various disorders that are herein disclosed.

PEPTIDOMIMETIC COMPOUNDS AND ANTIBODY-DRUG CONJUGATES THEREOF

This invention relates to peptidomimetic linkers and anti-body drug conjugates thereof, to pharmaceutical compositions containing them, and to their use in therapy for the prevention or treatment of cancer.

Deracemization and the first CD spectrum of a 310-helical peptide made of achiral α-amino-isobutyric acid residues in a chiral membrane mimetic environment

Interaction of the racemic helical homo-octapeptide made by the achiral Cα-methyl alanine (Aib) amino acid with a chiral enantiopure micellar aggregate made of N-dodecylproline led to the deracemization of the helical Aib sequence thus allowing

BENZIIMIDAZOLE AND IMIDAZOPYRIDINE DERIVATIVES AS SODIUM CHANNEL MODULATORS

The invention relates to benzimidazole and imidazopyridine derivatives, to their use in medicine, to compositions containing them, to processes for their preparation and to intermediates used in such processes. More particularly the invention relates to new Nav1.8 modulators of formula (I) or pharmaceutically acceptable salts thereof, wherein R1, R2, R3, R4, R5, R6, R7. X and Y are as defined in the description. Nav1.8 modulators are potentially useful in the treatment of a wide range of disorders, particularly pain.

Hydroxyl may not be indispensable for raltegravir: Design, synthesis and SAR Studies of raltegravir derivatives as HIV-1 inhibitors

A series of raltegravir derivatives 20-42 were prepared and systematically evaluated for their anti-HIV activity. The bioassay results showed that most of the compounds possess good to excellent anti-HIV activity. Especially, compounds 25 and 35 with subpicomole IC50 values seemed to be the most potent anti-HIV agents among all of the reported synthesized compounds. These compounds may therefore be considered as new potent anti-HIV agents. The 5-hydroxyl modification of raltegravir derivatives significantly increased the anti-HIV activity, which indicates that the hydroxyl may not be indispensable for raltegravir. The introducing of acyl at 5-position of raltegravir derivatives is favorable for antiviral activity. In addition, a high-throughput cell-based assay method with pseudotyped virus stocks was developed and used to identify HIV inhibitors.

NOVEL PYRIDINE DERIVATIVES

The invention relates to a compound of formula (I) wherein R1 to R4 are defined as in the description and in the claims. The compound of formula (I) can be used as a medicament.

PYRIDIN- 2 -AMIDES USEFUL AS CB2 AGONISTS

The invention relates to a compound of formula (I) wherein R1 to R4 are defined as in the description and in the claims. The compound of formula (I) can be used as a medicament.